A targeted gene expression biomarker predicts clinic low-risk meningioma recurrence
Neuro-Oncology · 2025
DOI: 10.1093/neuonc/noae198 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Minh P Nguyen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of California San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Meningioma, Neoplasm Recurrence, Local, Meningeal Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH grants.
Abstract (Originalsprache)
Background
Despite reassuring clinical and histological features, low-grade meningiomas can recur after surgery. Targeted gene expression profiling improves risk stratification of meningiomas, but the utility of this approach for clinical low-risk meningiomas is incompletely understood.
Methods
This was a multicenter retrospective cohort study of meningiomas from patients who were treated at 4 institutions from 1992 to 2023. Adult patients with newly diagnosed or recurrent World Health Organization (WHO) grade 1 meningiomas that were treated with gross total resection (GTR) or subtotal resection (STR), or newly diagnosed WHO grade 2 meningiomas that were treated with GTR, were included. A 34-gene expression biomarker and gene expression risk score (continuous from 0 to 1) was evaluated in all samples.
Results
The study cohort was comprised of 723 patients, none of which were used for discovery or training of the gene expression biomarker and 265 of which were previously unreported. There were 626 WHO grade 1 meningiomas, 490 with GTR and 126 with STR, and 97 WHO grade 2 meningiomas with GTR. Targeted gene expression profiling classified 51.3% of clinical low-risk meningiomas as molecular intermediate-risk and 9.5% as molecular high-risk. Combining the gene expression biomarker with the extent of resection revealed that 19.8% of clinical low-risk meningiomas had unfavorable local freedom from recurrence (LFFR) and overall survival (OS), including 7.1% of newly diagnosed WHO grade 1 meningiomas with GTR. The risk score was prognostic for LFFR (HR per 0.1 increase in risk score 1.89, 95% CI: 1.58–2.25) across all WHO grades, extents of resection, and newly diagnosed or recurrent presentations.
Conclusions
Targeted gene expression profiling can identify clinical low-risk meningiomas that are likely to recur after surgery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of California San Francisco, San Francisco, California, USA.
- Department of Neurological Surgery, University of California San Francisco, San Francisco, California, USA.
- Department of Radiation Oncology, University of California, San Francisco, San Francisco, California, USA.
- Department of Neurological Surgery, Northwestern University, Chicago, Illinois, USA.
- Department of Radiation Oncology, Ohio State University, Columbus, Ohio, USA.
- Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA.
ORCID-Profile: Joshua D Palmer, David R Raleigh
Förderung
- NCI NIH HHS
- NIH grants
Zitieren
APA
Nguyen, M. P., Morshed, R. A., Youngblood, M. W., Perlow, H. K., Lucas, C. G., Patel, A. J., Palmer, J. D., Horbinski, C. M., Magill, S. T., Chen, W. C., & Raleigh, D. R. (2025). A targeted gene expression biomarker predicts clinic low-risk meningioma recurrence. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae198
Vancouver
Nguyen MP, Morshed RA, Youngblood MW, Perlow HK, Lucas CG, Patel AJ, et al. A targeted gene expression biomarker predicts clinic low-risk meningioma recurrence. Neuro-Oncology. 2025. doi:10.1093/neuonc/noae198
BibTeX
@article{Nguyen2025,
author = {Nguyen, Minh P and Morshed, Ramin A and Youngblood, Mark W and Perlow, Haley K and Lucas, Calixto-Hope G and Patel, Akash J and Palmer, Joshua D and Horbinski, Craig M and Magill, Stephen T and Chen, William C and Raleigh, David R},
title = {A targeted gene expression biomarker predicts clinic low-risk meningioma recurrence},
journal = {Neuro-Oncology},
year = {2025},
doi = {10.1093/neuonc/noae198}
}
EUVIMED